Higher dose of Pfizer-Lilly drug helps reduce back pain in study

In this article:

Feb 19 (Reuters) - Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study.

However, a lower dose of the drug did not significantly help alleviate pain when compared with a placebo, the companies said. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

Advertisement